MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Search

Erasca Inc

Chiusa

2.43 -2.8

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

2.4

Massimo

2.74

Metriche Chiave

By Trading Economics

Entrata

-2.9M

-34M

Margine di Profitto

-768.16

Dipendenti

103

EBITDA

-2.5M

-38M

Raccomandazioni

By TipRanks

Raccomandazioni

Neutrale

Previsioni per 12 mesi

+39.48% upside

Dividendi

By Dow Jones

Utili prossimi

10 nov 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

242M

661M

Apertura precedente

5.23

Chiusura precedente

2.43

Punteggio Tecnico

By Trading Central

Fiducia

Bearish Evidence

Erasca Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

8 ott 2025, 20:45 UTC

Utili

Costco Wholesale Sales Climb in September, Early October

8 ott 2025, 20:12 UTC

I principali Market Mover
Acquisizioni, Fusioni, Takeovers

TaskUs Shares Fall After Holders Reject Take-Private Deal

8 ott 2025, 16:39 UTC

I principali Market Mover

Mining Shares Rise as Gold Prices Soar

8 ott 2025, 23:45 UTC

Discorsi di Mercato

Nikkei May Rise on Weaker Yen -- Market Talk

8 ott 2025, 23:43 UTC

Discorsi di Mercato

Gold Falls on Possible Profit-Taking -- Market Talk

8 ott 2025, 23:18 UTC

Acquisizioni, Fusioni, Takeovers

JD Logistics to Finance Acquisition Using Internal Funds

8 ott 2025, 23:17 UTC

Acquisizioni, Fusioni, Takeovers

JD Logistics to Buy On-Demand Delivery Services Business for US$270.0M

8 ott 2025, 23:16 UTC

Acquisizioni, Fusioni, Takeovers

JD Logistics to Buy JD.com's On-Demand Delivery Services Business Dajiang and Dasheng

8 ott 2025, 21:54 UTC

Discorsi di Mercato
Utili

James Hardie Could Beat Annual Earnings Goal -- Market Talk

8 ott 2025, 21:30 UTC

Discorsi di Mercato

Boab Metals Bull Delivers Second Upgrade in a Month -- Market Talk

8 ott 2025, 21:26 UTC

Discorsi di Mercato
Utili

Transurban's 1Q Traffic Growth Beats Hopes -- Market Talk

8 ott 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

8 ott 2025, 19:15 UTC

Discorsi di Mercato

Geopolitical Risk Supports Gains in Oil Futures -- Market Talk

8 ott 2025, 19:01 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Pull Back Ahead of Storage Data -- Market Talk

8 ott 2025, 18:47 UTC

Discorsi di Mercato

Coca-Cola North America Sales Buoy International Weakness -- Market Talk

8 ott 2025, 18:46 UTC

Acquisizioni, Fusioni, Takeovers

TaskUs: Neither Party Will Be Required to Pay Termination Fee as Result of Planned Mutual Decision to Terminate

8 ott 2025, 18:46 UTC

Acquisizioni, Fusioni, Takeovers

TaskUs Will Remain a Publicly Traded Co >TASK

8 ott 2025, 18:46 UTC

Acquisizioni, Fusioni, Takeovers

TaskUs Does Not Plan to Convene Another Special Meeting of Stockholders >TASK

8 ott 2025, 18:45 UTC

Acquisizioni, Fusioni, Takeovers

TaskUs Didn't Receive Votes Necessary to Approve Transaction Agreement With Affil of Blackstone >TASK

8 ott 2025, 18:07 UTC

Discorsi di Mercato

Mexico's Inflation Seen Edging Up in September -- Market Talk

8 ott 2025, 16:20 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Energy & Utilities Roundup: Market Talk

8 ott 2025, 16:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

8 ott 2025, 16:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

8 ott 2025, 15:57 UTC

Discorsi di Mercato

Oil Rises Despite U.S. Crude Stockpiles Build -- Market Talk

8 ott 2025, 15:56 UTC

Discorsi di Mercato

Teck Resources' Chile Mine Issues Appear Transitory -- Market Talk

8 ott 2025, 15:53 UTC

Discorsi di Mercato

Argentine Sovereign Debt Seen as Attractive -- Market Talk

8 ott 2025, 15:44 UTC

Acquisizioni, Fusioni, Takeovers

Staar Surgical: Broadwood's Proposal to Vote Down Merger Could Allow It to Take Control Without Paying Any Premium

8 ott 2025, 15:44 UTC

Acquisizioni, Fusioni, Takeovers

Staar Surgical Board and Management Disagree With Recommendation Issued by Glass Lewis >STAA

8 ott 2025, 15:43 UTC

Acquisizioni, Fusioni, Takeovers

STAAR Surgical Board Reiterates Unanimous Recommendation Holders Vote for Alcon Merger

8 ott 2025, 15:42 UTC

Acquisizioni, Fusioni, Takeovers

Oracle Is a Buy-the-Dip Opportunity, Analyst Says. How the Stock Could Rise 23%. -- Barrons.com

Confronto tra pari

Modifica del prezzo

Erasca Inc Previsione

Obiettivo di Prezzo

By TipRanks

39.48% in crescita

Previsioni per 12 mesi

Media 3.25 USD  39.48%

Alto 6 USD

Basso 1 USD

Basato su 4 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Erasca Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Neutrale

4 ratings

2

Acquista

1

Mantieni

1

Vendi

Punteggio Tecnico

By Trading Central

1.39 / 1.44Supporto e resistenza

A breve termine

Bearish Evidence

A termine intermedio

Weak Bearish Evidence

A lungo termine

Very Strong Bearish Evidence

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Erasca Inc

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
help-icon Live chat